Zavesca(R) (miglustat) Receives EU Approval For The Treatment Of Progressive Neurological Manifestations In Patients With Niemann-Pick Type C Disease

Actelion Ltd (SIX: ATLN) announced that Zavesca® (miglustat) has been approved in the European Union for the treatment of progressive neurological manifestations in adult patients and pediatric patients with Niemann-Pick type C disease (NPC). Zavesca® is the first treatment to be approved for patients with Niemann-Pick type C disease, a very rare, invariably progressive and eventually fatal neurodegenerative genetic disorder affecting both children and adults.

More: continued here

Filed under: Neurology / Neuroscience on February 2nd, 2009